0001209191-23-051695.txt : 20231003 0001209191-23-051695.hdr.sgml : 20231003 20231003184933 ACCESSION NUMBER: 0001209191-23-051695 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231002 FILED AS OF DATE: 20231003 DATE AS OF CHANGE: 20231003 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lennon David James CENTRAL INDEX KEY: 0001995275 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38560 FILM NUMBER: 231305947 MAIL ADDRESS: STREET 1: C/O AADI BIOSCIENCE, INC. STREET 2: 17383 SUNSET BLVD, SUITE A250 CITY: PACIFIC PALISADES STATE: CA ZIP: 90272 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aadi Bioscience, Inc. CENTRAL INDEX KEY: 0001422142 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 611547850 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 17383 SUNSET AVENUE STREET 2: SUITE A250 CITY: PACIFIC PALISADES STATE: CA ZIP: 90272 BUSINESS PHONE: 424-473-8055 MAIL ADDRESS: STREET 1: 17383 SUNSET AVENUE STREET 2: SUITE A250 CITY: PACIFIC PALISADES STATE: CA ZIP: 90272 FORMER COMPANY: FORMER CONFORMED NAME: Aerpio Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20170316 FORMER COMPANY: FORMER CONFORMED NAME: ZETA ACQUISITION CORP II DATE OF NAME CHANGE: 20071227 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-10-02 0 0001422142 Aadi Bioscience, Inc. AADI 0001995275 Lennon David James C/O AADI BIOSCIENCE, INC. 17383 SUNSET BOULEVARD, SUITE A250 PACIFIC PALISADES CA 90272 1 1 0 0 Chief Executive Officer 0 Restricted Stock Units 2023-10-02 4 A 0 32558 0.00 A Common Stock 32558 32558 D Stock Option (right to buy) 0.00 2023-10-02 4 A 0 490000 0.00 A 2033-10-02 Common Stock 490000 490000 D Each restricted stock unit ("RSU") represents a contingent right to receive one share of Aadi Bioscience, Inc. Common Stock. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the RSUs subject to the award shall vest on October 2, 2024. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2023 Inducement Equity Incentive Plan) through each applicable date, twenty-five percent (25%) of the shares subject to the option shall vest one (1) year after the Date of Grant, and one-forty-eighth (1/48th) of the shares subject to the option shall vest monthly thereafter on the same day of the month as the Date of Grant (and if there is no corresponding day, the last day of the month), such that the option will be fully vested and exercisable four (4) years from the Date of Grant. "Date of Grant" shall mean October 2, 2023. /s/ Stephen Rodin, as Attorney-in-Fact 2023-10-03